The Use of Pro-Angiogenic And/or Pro-Hypoxic MiRNAs As Tools to Monitor Patients with Diffuse Gliomas

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2022 Jun 10

PMID 35682718

Authors

Guenaelle Levallet

Fatemeh Dubois

Arthur Leclerc

Edwige Petit

Lien Bekaert

Maxime Faisant

Christian Creveuil

Evelyne Emery

Gerard Zalcman

Emmanuele Lechapt-Zalcman

Affiliations

Soon will be listed here.

Abstract

IDH (isocitrate dehydrogenase) mutation, hypoxia, and neo-angiogenesis, three hallmarks of diffuse gliomas, modulate the expression of small non-coding RNAs (miRNA). In this paper, we tested whether pro-angiogenic and/or pro-hypoxic miRNAs could be used to monitor patients with glioma. The miRNAs were extracted from tumoral surgical specimens embedded in the paraffin of 97 patients with diffuse gliomas and, for 7 patients, from a blood sample too. The expression of 10 pro-angiogenic and/or pro-hypoxic miRNAs was assayed by qRT-PCR and normalized to the miRNA expression of non-tumoral brain tissues. We confirmed in vitro that IDH in hypoxia (1% O, 24 h) alters pro-angiogenic and/or pro-hypoxic miRNA expression in HBT-14 (U-87 MG) cells. Then, we reported that the expression of these miRNAs is (i) strongly affected in patients with glioma compared to that in a non-tumoral brain; (ii) correlated with the histology/grade of glioma according to the 2016 WHO classification; and (iii) predicts the overall and/or progression-free survival of patients with glioma in univariate but not in a multivariate analysis after adjusting for sex, age at diagnosis, and WHO classification. Finally, the expression of miRNAs was found to be the same between the plasma and glial tumor of the same patient. This study highlights a panel of seven pro-angiogenic and/or pro-hypoxic miRNAs as a potential tool for monitoring patients with glioma.

Citing Articles

Different Approaches to Study Molecular Blueprint and Biological Behavior of Brain Tumors: Editorial to the Special Issue "Advances in Molecular Genetics of Brain Tumors".

Pecina-Slaus N, Jovcevska I Int J Mol Sci. 2023; 24(2).

PMID: 36674461 PMC: 9865200. DOI: 10.3390/ijms24020948.

References

Adlakha Y, Saini N . Brain microRNAs and insights into biological functions and therapeutic potential of brain enriched miRNA-128. Mol Cancer. 2014; 13:33. PMC: 3936914. DOI: 10.1186/1476-4598-13-33. View

Shang C, Hong Y, Guo Y, Liu Y, Xue Y . MiR-210 up-regulation inhibits proliferation and induces apoptosis in glioma cells by targeting SIN3A. Med Sci Monit. 2014; 20:2571-7. PMC: 4266365. DOI: 10.12659/MSM.892994. View

Molina-Pinelo S, Suarez R, Pastor M, Nogal A, Marquez-Martin E, Martin-Juan J . Association between the miRNA signatures in plasma and bronchoalveolar fluid in respiratory pathologies. Dis Markers. 2012; 32(4):221-30. PMC: 3826892. DOI: 10.3233/DMA-2011-0882. View

Shimono Y, Zabala M, Cho R, Lobo N, Dalerba P, Qian D . Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell. 2009; 138(3):592-603. PMC: 2731699. DOI: 10.1016/j.cell.2009.07.011. View

Komori T . The 2016 WHO Classification of Tumours of the Central Nervous System: The Major Points of Revision. Neurol Med Chir (Tokyo). 2017; 57(7):301-311. PMC: 5566703. DOI: 10.2176/nmc.ra.2017-0010. View

Li Y, Yan C, Fan J, Hou Z, Han Y . MiR-221-3p targets Hif-1α to inhibit angiogenesis in heart failure. Lab Invest. 2020; 101(1):104-115. DOI: 10.1038/s41374-020-0450-3. View

Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K . Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008; 18(10):997-1006. DOI: 10.1038/cr.2008.282. View

Ghosh G, Subramanian I, Adhikari N, Zhang X, Joshi H, Basi D . Hypoxia-induced microRNA-424 expression in human endothelial cells regulates HIF-α isoforms and promotes angiogenesis. J Clin Invest. 2010; 120(11):4141-54. PMC: 2964978. DOI: 10.1172/JCI42980. View

Salinas-Vera Y, Marchat L, Gallardo-Rincon D, Ruiz-Garcia E, Astudillo-de la Vega H, Echavarria-Zepeda R . AngiomiRs: MicroRNAs driving angiogenesis in cancer (Review). Int J Mol Med. 2018; 43(2):657-670. DOI: 10.3892/ijmm.2018.4003. View

10.

Quintavalle C, Garofalo M, Zanca C, Romano G, Iaboni M, Del Basso De Caro M . miR-221/222 overexpession in human glioblastoma increases invasiveness by targeting the protein phosphate PTPμ. Oncogene. 2011; 31(7):858-68. PMC: 4299860. DOI: 10.1038/onc.2011.280. View

11.

Wang X, Labussiere M, Valable S, Peres E, Guillamo J, Bernaudin M . IDH1(R132H) mutation increases U87 glioma cell sensitivity to radiation therapy in hypoxia. Biomed Res Int. 2014; 2014:198697. PMC: 4033346. DOI: 10.1155/2014/198697. View

12.

Iuchi T, Sugiyama T, Ohira M, Kageyama H, Yokoi S, Sakaida T . Clinical significance of the 2016 WHO classification in Japanese patients with gliomas. Brain Tumor Pathol. 2018; 35(2):71-80. DOI: 10.1007/s10014-018-0309-0. View

13.

Behl T, Kumar C, Makkar R, Gupta A, Sachdeva M . Intercalating the Role of MicroRNAs in Cancer: As Enemy or Protector. Asian Pac J Cancer Prev. 2020; 21(3):593-598. PMC: 7437313. DOI: 10.31557/APJCP.2020.21.3.593. View

14.

Ma X, Yoshimoto K, Guan Y, Hata N, Mizoguchi M, Sagata N . Associations between microRNA expression and mesenchymal marker gene expression in glioblastoma. Neuro Oncol. 2012; 14(9):1153-62. PMC: 3424211. DOI: 10.1093/neuonc/nos145. View

15.

Fasanaro P, Greco S, Lorenzi M, Pescatori M, Brioschi M, Kulshreshtha R . An integrated approach for experimental target identification of hypoxia-induced miR-210. J Biol Chem. 2009; 284(50):35134-43. PMC: 2787374. DOI: 10.1074/jbc.M109.052779. View

16.

Rezaei O, Honarmand K, Nateghinia S, Taheri M, Ghafouri-Fard S . miRNA signature in glioblastoma: Potential biomarkers and therapeutic targets. Exp Mol Pathol. 2020; 117:104550. DOI: 10.1016/j.yexmp.2020.104550. View

17.

Han I, Kim M, Lee S, Kim J, Kim S, Chang J . Down-regulation of MicroRNA-126 in Glioblastoma and its Correlation with Patient Prognosis: A Pilot Study. Anticancer Res. 2016; 36(12):6691-6697. DOI: 10.21873/anticanres.11280. View

18.

Miska E . How microRNAs control cell division, differentiation and death. Curr Opin Genet Dev. 2005; 15(5):563-8. DOI: 10.1016/j.gde.2005.08.005. View

19.

Zhang H, Wang J, Wang Z, Ruan C, Wang L, Guo H . Serum miR-100 is a potential biomarker for detection and outcome prediction of glioblastoma patients. Cancer Biomark. 2018; 24(1):43-49. DOI: 10.3233/CBM-181416. View

20.

Cheng W, Ren X, Zhang C, Han S, Wu A . Expression and prognostic value of microRNAs in lower-grade glioma depends on IDH1/2 status. J Neurooncol. 2017; 132(2):207-218. DOI: 10.1007/s11060-016-2368-6. View